An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay. Read more about An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
Identifying multi-level social determinants for disparities in survival and patient-reported outcomes in national head and neck cancer trials. Read more about Identifying multi-level social determinants for disparities in survival and patient-reported outcomes in national head and neck cancer trials.
Analysis of evidence in NCCN harmonized guidelines for sub-Saharan Africa. Read more about Analysis of evidence in NCCN harmonized guidelines for sub-Saharan Africa.
FACS-based whole-genome CRISPRi screen to uncover STEAP1 regulators in prostate cancer. Read more about FACS-based whole-genome CRISPRi screen to uncover STEAP1 regulators in prostate cancer.
A phase 1 dose-escalation study of GCC19CART: A novel CAR T-cell therapy for metastatic colorectal cancer in the United States. Read more about A phase 1 dose-escalation study of GCC19CART: A novel CAR T-cell therapy for metastatic colorectal cancer in the United States.
Improving patient outcomes by assessing unmet social needs: A preliminary study in a urologic oncology clinic. Read more about Improving patient outcomes by assessing unmet social needs: A preliminary study in a urologic oncology clinic.
Early adverse symptoms to predict response to treatment among patients in the I-SPY trial. Read more about Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.
Transcriptional profiling to identify a program of enzalutamide extreme non-response in lethal prostate cancer. Read more about Transcriptional profiling to identify a program of enzalutamide extreme non-response in lethal prostate cancer.
Neutrophil-to-lymphocyte ratio as a predictor of response and toxicity in T-cell engager therapy for solid tumors. Read more about Neutrophil-to-lymphocyte ratio as a predictor of response and toxicity in T-cell engager therapy for solid tumors.
Molecular characterization of STEAP1 and -2 in advanced prostate cancer. Read more about Molecular characterization of STEAP1 and -2 in advanced prostate cancer.
